Abstract: A computing system is configured to detect irregular yawing at wind turbines. To this end, the computing system (i) for each respective turbine of an identified cluster of wind turbines: (a) obtains yaw-activity data indicative of the respective turbine's yaw activity during a window of time, and (b) based on obtained yaw-activity data, derives a yaw-activity-measure dataset having measures of the respective turbine's yaw activity during time intervals within the window of time, (ii) based on the respective yaw-activity-measure datasets for the turbines in the cluster, derives a cluster-level yaw-activity-measure dataset, (iii) evaluates the respective yaw-activity-measure dataset for one or more turbines in the cluster as compared to the cluster-level yaw-activity-measure dataset, (iv) based on the evaluation, identifies at least one turbine of the cluster that exhibited irregular yaw activity, and (v) transmits, to an output device, a notification of the irregular yaw activity at the at least one turbine.

Abstract: Fusion proteins containing a PDGF binding portion, a VEGF binding portion, and an Fc antibody region are described. Also described are nucleic acids encoding the fusion proteins, compositions comprising the fusion proteins, and methods of using the fusion proteins for treating or preventing clinical conditions characterized by abnormal angiogenesis, such as vascular permeability, edema or inflammation.

Abstract: A computing system is configured to detect irregular yawing at wind turbines. To this end, the computing system (i) for each respective turbine of an identified cluster of wind turbines: (a) obtains yaw-activity data indicative of the respective turbine's yaw activity during a window of time, and (b) based on obtained yaw-activity data, derives a yaw-activity-measure dataset having measures of the respective turbine's yaw activity during time intervals within the window of time, (ii) based on the respective yaw-activity-measure datasets for the turbines in the cluster, derives a cluster-level yaw-activity-measure dataset, (iii) evaluates the respective yaw-activity-measure dataset for one or more turbines in the cluster as compared to the cluster-level yaw-activity-measure dataset, (iv) based on the evaluation, identifies at least one turbine of the cluster that exhibited irregular yaw activity, and (v) transmits, to an output device, a notification of the irregular yaw activity at the at least one turbine.

Abstract: The present invention relates to a biologic that inhibits angiogenesis. In particular, the present invention relates to fusion proteins that inhibit the integrin activated pathway and one other angiogenic factor-activated pathway, the compositions of these fusion proteins, as well as methods for producing and using the same.

Abstract: A computing system is configured to detect irregular yawing at wind turbines. To this end, the computing system (i) for each respective turbine of an identified cluster of wind turbines: (a) obtains yaw-activity data indicative of the respective turbine's yaw activity during a window of time, and (b) based on obtained yaw-activity data, derives a yaw-activity-measure dataset having measures of the respective turbine's yaw activity during time intervals within the window of time, (ii) based on the respective yaw-activity-measure datasets for the turbines in the cluster, derives a cluster-level yaw-activity-measure dataset, (iii) evaluates the respective yaw-activity-measure dataset for one or more turbines in the cluster as compared to the cluster-level yaw-activity-measure dataset, (iv) based on the evaluation, identifies at least one turbine of the cluster that exhibited irregular yaw activity, and (v) transmits, to an output device, a notification of the irregular yaw activity at the at least one turbine.

Abstract: The present invention relates to a biologic that inhibits angiogenesis. In particular, the present invention relates to fusion proteins that inhibit the integrin activated pathway and one other angiogenic factor-activated pathway, the compositions of these fusion proteins, as well as methods for producing and using the same.

Abstract: The present invention relates to a biologic that inhibits angiogenesis. In particular, the present invention relates to fusion proteins that inhibit the integrin activated pathway and one other angiogenic factor-activated pathway, the compositions of these fusion proteins, as well as methods for producing and using the same.

Abstract: The present invention relates to a biologic that inhibits angiogenesis. In particular, the present invention relates to fusion proteins that inhibit the integrin activated pathway and one other angiogenic factor-activated pathway, the compositions of these fusion proteins, as well as methods for producing and using the same.

Abstract: Fusion proteins containing a PDGF binding portion, a VEGF binding portion, and an Fc antibody region are described. Also described are nucleic acids encoding the fusion proteins, compositions comprising the fusion proteins, and methods of using the fusion proteins for treating or preventing clinical conditions characterized by abnormal angiogenesis, such as vascular permeability, edema or inflammation.